Physician profile
Roger Horioglu
NPI 1932180015
$21,500.74
in general payments reported to CMS, 2019-2025
22 companies · $1,579 in 2025
The $1,579 reported for 2025 was more than what 87% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $314 · 2020: $308 · 2021: $857 · 2022: $16K · 2023: $1,207 · 2024: $1,262 · 2025: $1,579.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,048.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,047.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $15,048.87 | 2021-2022 | |
| Genzyme Corporation | $1,975.38 | 2020-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,176.38 | 2020-2025 | Dupixent |
| Optinose US, INC. | $664.37 | 2019-2025 | |
| Glaxosmithkline, LLC. | $582.59 | 2021-2025 | Nucala |
| Merz North America, INC. | $446.29 | 2021-2025 | Xeomin |
| Abbvie INC. | $441.86 | 2023-2025 | |
| Stryker Corporation | $359.18 | 2019-2025 | Xpress Loprofile |
| Vertex Pharmaceuticals Incorporated | $128.56 | 2025 | |
| Inspire Medical Systems, INC. | $123.53 | 2025 | Inspire |
| Acclarent, INC | $122.03 | 2019-2021 | |
| Galderma Laboratories, L.P. | $98.36 | 2024-2025 | Dysport |
| Alk-Abello, INC | $61.18 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $45.56 | 2022 | |
| Hikma Pharmaceuticals USA | $39.33 | 2022-2023 | Ryaltris |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Integra Lifesciences Corporation | $37.95 | 2025 | Trudi Probe, Relieva Spinplus Nav, Inspira Air |
| Medtronic, INC. | $33.03 | 2024 | Propel |
| Intersect Ent, INC. | $27.16 | 2020 | |
| Phathom Pharmaceuticals, INC. | $24.69 | 2025 | Voquezna |
| Novartis Pharmaceuticals Corporation | $24.08 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $21.67 | 2025 | Tezspire |
| Amgen INC. | $18.69 | 2025 | Tezspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roger Horioglu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.